HOME >> MEDICINE >> NEWS
Potentially fatal toxicities occur with off-label use of cancer drugs

CHICAGO --- Food and Drug Administration policies prevent pharmaceutical manufacturers from informing patients about potentially fatal toxicities that occur with some cancer drugs -- policies that should be revised immediately, according to Northwestern University researchers.

Andrew M. Evens, D.O., instructor in medicine, and Charles L. Bennett, M.D., professor of medicine, Northwestern University Feinberg School of Medicine, have called for an immediate revision of these FDA policies, particularly because the drug thalidomide, which was approved by the FDA as an off-label cancer treatment in 1998, has been reported to have caused potentially fatal blood clots in the legs and the lungs in over 190 cancer patients.

Virtually all patients who have received thalidomide over the past six years have received the drug for cancer, making this drug the only one in the country whose use is exclusively off label.

The FDA strictly restricts discussion or dissemination of information to physicians and patients to "on label" indications, which prevents the pharmaceutical manufacturer from advising cancer patients about the side effects of thalidomide when it is used to treat cancer.

Moreover, despite an FDA mandate that all health care personnel and patients involved with thalidomide treatments participate in the preventive System for Thalidomide Education and Prescribing Safety (STEPS), the program does not provide patients, pharmacists or health care providers with information on thromboembolisms.

Evens presented the RADAR (Research on Adverse Drug Events and Reports) data on the thalidomide-associated blood clots on at the 46th Annual Meeting of the American Society of Hematology in early December.

The Northwestern study identified the occurrence of potential fatal blood clots in the legs and the lungs in up to 20 percent or more of cancer patients who received thalidomide.

The highest rates of thromboembolism occurred in pati
'"/>

Contact: Elizabeth Crown
e-crown@northwestern.edu
312-503-8928
Northwestern University
20-Dec-2004


Page: 1 2

Related medicine news :

1. Potentially blinding eye disease more prevalent than previously thought
2. Increased Public Access To Defibrillation Could Prove Potentially Cost-Effective And Life-Saving
3. Anti-Clotting Drug May Cause Potentially Fatal Platelet Disorder
4. New marrow transplant method developed at Stanford may eliminate fatal side effects
5. Study finds HER2-positive breast cancer invades organs due to fatal chemical attraction
6. NIAID forms network to tackle potentially fatal reaction to smallpox vaccine
7. Promising drug fails to thwart fatal lung disease in large trial
8. National study seeks cause of baffling, fatal disorder called multiple system atrophy
9. Vaccines against fatal African cattle fever
10. Heart failure is more common but less fatal in South Asian people
11. Coronary artery calcium can be a warning sign of fatal cardiac event

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/14/2019)... ... November 14, 2019 , ... With Giving Tuesday on Dec. ... businesses and organizations about the benefits of supporting local hospitalized veterans throughout Maryland. ... millions of people to give, collaborate and celebrate generosity before the holidays, and ...
(Date:11/14/2019)... ... , ... EMulate Therapeutics, Inc., a clinical-stage therapeutic device company ... 5 poster presentations related to its medical devices for treating adult and pediatric ... Phoenix, beginning on November 20 . , Two posters will be ...
(Date:11/14/2019)... ... November 14, 2019 , ... ... Administration (FDA) has granted acceptance to file status of its application for the ... in the disease neurofibromatosis type one (NF1). The FDA’s acceptance of the application ...
(Date:11/12/2019)... ... , ... AI for preventable harm analytics leader Jvion today announced that Jvion ... the Potential of AI”, which provides a “tip of the spear” analysis of the ... enough clients to complete a full KLAS analysis, Jvion was featured as having “by ...
(Date:11/12/2019)... TORONTO (PRWEB) , ... November 12, 2019 , ... ... of a clinical study. With increasing site activation cycle times, extended contract negotiations ... study start-up is an area of clinical operations that’s ripe for improvement. Following ...
Breaking Medicine News(10 mins):
(Date:11/11/2019)... ... November 11, 2019 , ... Oak Street Health , a network of ... new centers in Greensboro and Charlotte, with an additional center in Charlotte under development. ... different model of care that emphasizes quality of care rather than quantity of services. ...
(Date:11/11/2019)... ... November 11, 2019 , ... ... mutual agreement to facilitate the coordination and implementation of joint projects for ... medicinal products. These undertakings will empower biomedical professionals to leverage their roles ...
(Date:11/11/2019)... (PRWEB) , ... November 10, 2019 , ... ... rebranding alongside a redesign of its website , which features over 600 ... from the brand's 35+ year commitment to providing high-quality health and wellness products, ...
Breaking Medicine Technology:
Cached News: